Hormonal
Anti-obesity medications (AOMs) including liraglutide, semaglutide, and tirzepatide demonstrate efficacy and safety for chronic weight management in randomized controlled trials lasting over one year.
If you are prescribed an FDA-approved anti-obesity medication like semaglutide or tirzepatide, expect it to be a long-term treatment. These drugs have been shown to be safe and effective for weight management over periods of 1-5 years in clinical trials. Because obesity is chronic, stopping the medication often leads to weight regain, so plan for ongoing use and address insurance/access issues early.
A significant body of evidence from randomized controlled trials has supported the efficacy and safety of Food and Drug Administration (FDA)-approved AOMs for chronic weight management, including liraglutide (2014), semaglutide (2021), and tirzepatide (2023).
Why this rating
Cites multiple large-scale, long-duration RCTs (SCALE, SELECT, SURMOUNT-4).
Source
Response to the Letter to the Editor by Bett et al.
Jaime P. Almandoz et al. · Obesity · 2024
DOI 10.1002/oby.24140
More from this paper
- Dietary fiber intake must be accompanied by adequate water intake to prevent constipation, a common adverse event of anti-obesity medications.Good
- Energy intake goals for obesity treatment should be personalized, but general guidance based on sex is currently the standard in evidence-based guidelines.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →